Tesamorelin

Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analogue peptide used in endocrine research, particularly studies of visceral adiposity in antiretroviral treated populations; the catalogue label denotes the research grade peptide.

Tesamorelin is associated with growth hormone research as a synthetic GHRH analogue. Randomised studies in antiretroviral treated adults with HIV associated lipodystrophy found reduced visceral adipose tissue, with some lipid and liver fat findings also studied. FDA authorised Egrifta WR/SV products are indicated to reduce excess abdominal fat in HIV infected adults with lipodystrophy; this does not establish authorisation for general weight loss or for a catalogue material.

Tesamorelin: Batch documents are not yet linked on this site. Required evidence for this synthetic GHRH analogue peptide comprises batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water details; and potency/assay method used for release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.

Tesamorelin: Storage depends on the documented supplied presentation; for this synthetic GHRH analogue peptide confirm dry/lyophilised versus solution form, counterion and concentration, solvent or buffer choice, pH sensitivity, container closure compatibility and freeze/thaw behaviour which together determine aggregation and chemical stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.